MELBOURNE, Australia,
June 21, 2012 /PRNewswire-Asia/ --
Bluechiip Limited (ASX: BCT) - which has developed a unique
asset-tracking solution initially for cryogenic sample management
in the healthcare and life science industry - today announced that
a successful pilot trial of its tracking solution by ATCC
(www.atcc.org), a US-based leader in biological materials
management and processes, has led to the first sales order for
Bluechiip's products from ATCC.
ATCC is purchasing the bluechiip® solution so that they may be
an early adopter of the bluechiip® technology and to facilitate
enhancement of cryogenic sample management and bench research via
temperature evaluation and tracking.
ATCC stores approximately 10 million biological samples of
different formats. The repository portion of its facility contains
200 freezers to store biomaterials, including vapor-phase liquid
nitrogen freezers, mechanical freezers and cold rooms. End users of
these products and services originate from over 140 countries and
include researchers in academia and government, as well as private
industry. ATCC's collections encompass a wide range of biological
materials for research, including but not limited to cell lines,
microorganisms and bioproducts.
The pilot trial was a collaboration sponsored by Bluechiip, ATCC
and Corning Life Sciences. The robust study was conducted at ATCC's
biological resource facility in Manassas,
Virginia. The pilot trial evaluated the bluechiip®
technology across a comprehensive range of cryogenic sample
management and cold chain processes. The pilot trial verified the
bluechiip® tracking solution - which enables sample identification
and temperature information to be read at temperatures as low as
those reached in liquid nitrogen, approximately -196 degrees
Celsius and enables data to be transmitted through frost.
Bluechiip's Managing Director, Brett
Schwarz, said: "We are excited to receive our first sales
order, particularly from a world leader in our first targeted
market of biobanking and biorepositories. This is validation of the
enormous potential and wideranging applications of the bluechiip®
tracking solution."
Kathleen Wyatt, Manager,
Inventory Control and Respository Operations, ATCC, said, "ATCC has
a long history of exploring inventive and forward-thinking
technologies in biological materials management. Bluechiip is
elevating cold chain custody and temperature tracking to an
exciting new level. This endeavour with Bluechiip has the potential
to enhance future offerings by ATCC."
About Bluechiip Limited:
Bluechiip has developed a wireless tracking solution with
temperature sensing capabilities for the healthcare and life
science, security, defence and manufacturing industries which
represents a generational change from current methods such as
labels (hand-written and pre-printed), barcodes (linear and 2D) and
microelectronic integrated circuit (IC)-based RFID (Radio Frequency
Identification).
The unique tag is based on MEMS technology and contains no
electronics. The tag can either be embedded or manufactured into a
storage product, such as vials or bags. Easy identification, along
with any associated information from the tag such as temperature
can be detected by a reader, which can also sense the temperature
of the tagged items. The traditional identification technologies
have significant limitations. Whereas a barcode requires a visible
tag or line-of-sight optical scan, bluechiip® technology does not.
Unlike labels, barcodes and RFID, the bluechiip® technology can
sense the temperature of each item a tag is attached to, or
embedded in.
The bluechiip® technology has initial applications in the
healthcare industry particularly those businesses which require
cryogenic storage facilities (biobanks and biorepositories).
bluechiip® offers the only technology that enables accurate and
reliable tracking of products including stem cells, cord blood, and
other biospecimens. In addition to functioning in extreme
temperatures, the bluechiip® tracking solution can survive
autoclaving, gamma irradiation sterilization, humidification,
centrifuging, cryogenic storage and frosting. The bluechiip®
technology has other healthcare applications in pathology, clinical
trials and forensics. Several other key markets outside of
healthcare include coldchain logistics/supply chain,
security/defence, industrial/manufacturing and
aerospace/aviation.
Further information is available at www.bluechiip.com
For more information:
Brett
Schwarz
|
Richard
Allen
|
Managing
Director, Bluechiip Limited
|
Oxygen
Financial Public Relations
|
Ph:
+61-419-367-590
|
Ph:
+61-3-9915-6341
|
brett.schwarz@bluechiip.com
|
richard@oxygenpr.com.au
|
SOURCE Bluechiip Limited